Oxidien Among Top Three Winners of Digital RESI June Innovation Challenge

The 3-day Digital RESI June conference announced the Top 3 Winners of the Innovation Challenge. UF Innovate | The Hub resident client Oxidien Pharmaceuticals was among the winners.

Watch Oxidien’s virtual poster, short pitch, and other supplementary materials here.

Oxidien Pharmaceuticals is a clinical-stage drug development company developing a treatment for enteric hyperoxaluria, a large unmet need in kidney disease. The company has excellent safety and efficacy data using proprietary, oral biologic with significant advantages over products in development. Enteric hyperoxaluria is a condition that affects 250,000 patients in the US alone. The company spun out from Captozyme, Inc., in 2019, before Captozyme was acquired by Arranta Bio in November of 2019.

Learn more about Oxidien Among Top Three Winners of Digital RESI June Innovation Challenge.